- Conditions
- Healthy Adult Volunteers
- Interventions
- BMS-986090, Placebo matching with BMS-986090, Keyhole limpet hemocyanin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 2,338
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 34
- States / cities
- Mesa, Arizona • Fresno, California • Greenbrae, California + 29 more
- Conditions
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Interventions
- Tolinapant, Decitabine + Cedazuridine
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more
- Conditions
- Advanced Solid Tumor, NSCLC
- Interventions
- CLN-619, Pembrolizumab, Paclitaxel, Carboplatin AUC 6, pemetrexed, Datopotamab deruxtecan-dlnk (Dato-DXd)
- Drug
- Lead sponsor
- Cullinan Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Duarte, California • Irvine, California + 9 more
- Conditions
- Moderate to Severe Osteoarthritis
- Interventions
- SM04690, 0.03mg/2mL, SM04690, 0.07mg/2mL, SM04690, 0.23mg/2mL, Placebo
- Drug
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • El Cajon, California • Walnut Creek, California + 4 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- BAY1436032
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Buffalo, New York • New York, New York • The Bronx, New York + 4 more
- Conditions
- Fabry Disease
- Interventions
- PRX-102 1 mg/kg every two weeks
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more
- Conditions
- X-Linked Adrenoleukodystrophy, Adrenomyeloneuropathy
- Interventions
- Sobetirome
- Drug
- Lead sponsor
- Thomas S. Scanlan
- Other
- Eligibility
- 18 Years to 64 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Gastroesophageal Reflux
- Interventions
- Rabeprazole sodium
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Up to 44 Weeks
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 10
- States / cities
- Orange, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
- Conditions
- Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
- Interventions
- MT-8421, Nivolumab
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Modesto, California • Westminster, California + 13 more
- Conditions
- Diabetes
- Interventions
- Wosulin R, Actrapid
- Biological
- Lead sponsor
- Wockhardt
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- RGX-202
- Genetic
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 1 Year and older · Male only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Orange, California • Palo Alto, California + 16 more
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Pasadena, California + 10 more
- Conditions
- Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
- Interventions
- TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 9
- States / cities
- Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 13 more
- Conditions
- Plaque Psoriasis
- Interventions
- PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Toledo, Ohio + 2 more
- Conditions
- Cardiovascular Disease
- Interventions
- Fx-5A peptide complex
- Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alzheimer Disease, Parkinson Disease
- Interventions
- Posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 13
- States / cities
- Stamford, Connecticut • DeLand, Florida • Hallandale, Florida + 9 more
- Conditions
- Hepatitis C Virus
- Interventions
- Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 22
- States / cities
- Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more
- Conditions
- Diabetes Mellitus
- Interventions
- HM11260C, Placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Ohio City, Ohio
- Conditions
- Acute Myocardial Infarction
- Interventions
- INO-1001
- Drug
- Lead sponsor
- Inotek Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 10
- States / cities
- Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more
- Conditions
- Fabry Disease
- Interventions
- Migalastat HCl 150 mg
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 4 more